ReviewNature reviews. Cardiology2011
Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease.
Review in Nature reviews. Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 86 citations in OpenAlex.
- Results from the SCIENCE and Danish ASC trials using allogeneic mesenchymal stromal cells to treat ischemic heart failure patients.Regenerative medicine · 2025Trial
- Plasma Small Extracellular Vesicle Cardiac miRNA Expression in Patients with Ischemic Heart Failure, Randomized to Percutaneous Intramyocardial Treatment of Adipose Derived Stem Cells or Placebo: Subanalysis of the SCIENCE Study.International journal of molecular sciences · 2023Trial
- Local electromechanical alterations determine the left ventricle rotational dynamics in CRT-eligible heart failure patients.Scientific reports · 2021Trial
- Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure.Disease markers · 2019Trial
- Effects of Transendocardial CD34Stem cells translational medicine · 2017Trial
- Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance.Stem cells translational medicine · 2016Trial
- Trial
- Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.Circulation research · 2014Trial
- Maturation of pluripotent stem cell-derived cardiomyocytes: limitations and challenges from metabolic aspects.Stem cell research & therapy · 2024Review
- Transcatheter targeted myocardial restoration using hydrogel-based cell-free compound: Toward an adoptable clinical protocol.JTCVS open · 2023Article
- BMP2 gene transfer induces pericardial effusion and inflammatory response in the ischemic porcine myocardium.Frontiers in cardiovascular medicine · 2023Article
- Left ventricular electrical potential measured by the NOGA XP electromechanical mapping method as a predictor of response to cardiac resynchronization therapy.Frontiers in cardiovascular medicine · 2023Article
- AAV2-VEGF-B gene therapy failed to induce angiogenesis in ischemic porcine myocardium due to inflammatory responses.Gene therapy · 2022Article
- The cell-autonomous and non-cell-autonomous roles of the Hippo pathway in heart regeneration.Journal of molecular and cellular cardiology · 2022Review
- Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data.Journal of clinical medicine · 2022Article
- Prototype device for endoventricular beta-emitting radiotracer detection and molecularly-guided intervention.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Progress in Bioengineering Strategies for Heart Regenerative Medicine.International journal of molecular sciences · 2022Review
- Nuclear Cardiac Imaging in the Interventional Suite.Current cardiology reports · 2022Review
- Cell-Based HIF1α Gene Therapy Reduces Myocardial Scar and Enhances Angiopoietic Proteome, Transcriptomic and miRNA Expression in Experimental Chronic Left Ventricular Dysfunction.Frontiers in bioengineering and biotechnology · 2022Article
- Tracking Early Systolic Motion for Assessing Acute Response to Cardiac Resynchronization Therapy in Real Time.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The three-dimensional NOGA(®) (Biologics Delivery Systems, a Johnson & Johnson company, Irwindale, CA, USA) electromechanical mapping system simultaneously registers the electrical and mechanical activities of the left ventricle, enabling online assessment of myocardial viability. The system distinguishes between viable, nonviable, stunned, and hibernating myocardium and can assess wall motion. The evaluation of the electrophysiological state of the tissue by NOGA(®) mapping has been validated by comparing the electroanatomical voltage and local linear shortening maps obtained with this technique with several noninvasive diagnostic tests. Bipolar signal analysis and determination of the existence and degree of transmural infarctions are also possible with NOGA(®). Immediately after percutaneous coronary intervention, an increased electromechanical discordance between voltage and local linear shortening maps indicates procedure-induced stunning that is caused by repetitive ischemia or microvascular compromise. Catheter-based direct intramyocardial injection of cells or gene constructs by NOGA(®) reduces the likelihood of systemic toxicity of the injected substance, resulting in minimal washout, limited exposure of nontarget organs, and precise localization to ischemic and peri-ischemic myocardial regions in patients with chronic myocardial ischemia. In addition, direct intramyocardial injection enables the treatment of chronic myocardial infarction by provoking a chemotactic signal at the injection-injury site that contributes to cell engraftment. By measuring the electrical activation pattern in delayed-motion areas, NOGA(®) might also be useful to predict response to cardiac resynchronization therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.